Drugs in development for toxoplasmosis: advances, challenges, and current status

References

• TenterAMHeckerothARWeissLMToxoplasma gondii: from animals to humansInt J Parasitol20003012–131217125811113252
   PubMed Web of Science ®Google Scholar
• JonesJLAksteinRBHlavsaMCLopezASWilsonMHollandGNFollow-up of the 1977 Georgia outbreak of toxoplasmosisAm J Trop Med Hyg20169461299130027044565
   PubMed Web of Science ®Google Scholar
• VaudauxJDMuccioliCJamesERIdentification of an atypical strain of toxoplasma gondii as the cause of a waterborne outbreak of toxoplasmosis in Santa Isabel do Ivai, BrazilJ Infect Dis201020281226123320836703
   PubMed Web of Science ®Google Scholar
• BowieWRKingASWerkerDHOutbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation TeamLancet199735090721731779250185
   PubMed Web of Science ®Google Scholar
• PappasGRoussosNFalagasMEToxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosisInt J Parasitol200939121385139419433092
   PubMed Web of Science ®Google Scholar
• DubeyJPLagoEGGennariSMSuCJonesJLToxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiologyParasitology2012139111375142422776427
   PubMed Web of Science ®Google Scholar
• JonesJLKruszon-MoranDRiveraHNPriceCWilkinsPPToxoplasma gondii seroprevalence in the United States 2009–2010 and comparison with the past two decadesAm J Trop Med Hyg20149061135113924710615
   PubMed Web of Science ®Google Scholar
• KhanAJordanCMuccioliCGenetic Divergence of Toxoplasma gondii Strains Associated with Ocular Toxoplasmosis, BrazilEmerging Infectious Diseases200612694294916707050
   PubMed Web of Science ®Google Scholar
• DemarMHommelDDjossouFAcute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French GuianaClin Microbiol Infect2012187E221E23121958195
   PubMed Web of Science ®Google Scholar
• JonesJLHollandGNAnnual burden of ocular toxoplasmosis in the USAm J Trop Med Hyg201082346446520207874
   PubMed Web of Science ®Google Scholar
• Robert-GangneuxFDardeMLEpidemiology of and diagnostic strategies for toxoplasmosisClin Microbiol Rev201225226429622491772
   PubMed Web of Science ®Google Scholar
• CoccaroEFLeeRGroerMWCanACoussons-ReadMPostolacheTTToxoplasma gondii infection: relationship with aggression in psychiatric subjectsJ Clin Psychiatry201677333434127046307
   PubMed Web of Science ®Google Scholar
• SugdenKMoffittTEPintoLPoultonRWilliamsBSCaspiAIs Toxoplasma gondii infection related to brain and behavior impairments in humans? Evidence from a population-representative birth cohortPLoS One2016112e014843526886853
   PubMed Web of Science ®Google Scholar
• SutterlandALFondGKuinABeyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysisActa Psychiatr Scand2015132316117925877655
   PubMed Web of Science ®Google Scholar
• RabaudCMayTAmielCExtracerebral toxoplasmosis in patients infected with HIV. A French National SurveyMedicine (Baltimore)19947363063147984082
   PubMed Web of Science ®Google Scholar
• GrantIHGoldJWRosenblumMNiedzwieckiDArmstrongDToxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDSAIDS1990465195212386617
   PubMed Web of Science ®Google Scholar
• MeleAPatersonPJPrenticeHGLeoniPKibblerCCToxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literatureBone Marrow Transplant20022969169812180115
   PubMed Web of Science ®Google Scholar
• MartinoRMaertensJBretagneSToxoplasmosis after hematopoietic stem cell transplantationClin Infect Dis2000311188119511073751
   PubMed Web of Science ®Google Scholar
• MartinoRBretagneSEinseleHEarly detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantationClin Infect Dis2005401677815614694
   PubMed Web of Science ®Google Scholar
• MartinoRBretagneSRoviraMToxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplant2000251111111410828877
   PubMed Web of Science ®Google Scholar
• GajurelKDhakalRMontoyaJGToxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendationsCurr Opin Infect Dis201528428329226098500
   PubMed Web of Science ®Google Scholar
• JonesJLRobertsJMToxoplasmosis hospitalizations in the United States, 2008, and trends, 1993–2008Clin Infect Dis2012547e58e6122267718
   PubMed Web of Science ®Google Scholar
• HoffmannSBatzMBMorrisJGJrAnnual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogensJ Food Prot20127571292130222980013
   PubMed Web of Science ®Google Scholar
• McLeodRBoyerKKarrisonTOutcome of treatment for congenital toxoplasmosis, 1981–2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis StudyClin Infect Dis200642101383139416619149
   PubMed Web of Science ®Google Scholar
• CarmeBDemarMAjzenbergDDardeMLSevere acquired toxoplasmosis caused by wild cycle of Toxoplasma gondii, French GuianaEmerg Infect Dis200915465665819331765
   PubMed Web of Science ®Google Scholar
• KhanAAjzenbergDMercierAGeographic separation of domestic and wild strains of Toxoplasma gondii in French Guiana correlates with a monomorphic version of chromosome1aPLoS Negl Trop Dis201489e318225233228
   PubMed Web of Science ®Google Scholar
• DemarMAjzenbergDMaubonDFatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspectsClin Infect Dis2007457e88e9517806043
   PubMed Web of Science ®Google Scholar
• PorterSBSandeMAToxoplasmosis of the central nervous system in the acquired immunodeficiency syndromeN Engl J Med199232723164316481359410
   PubMed Web of Science ®Google Scholar
• KatlamaCDe WitSO’DohertyEVan GlabekeMClumeckNPyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDSClin Infect Dis19962222682758838183
   PubMed Web of Science ®Google Scholar
• DannemannBMcCutchanJAIsraelskiDTreatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment GroupAnn Intern Med1992116133431727093
   PubMed Web of Science ®Google Scholar
• BeraudGPierre-FrancoisSFoltzerACotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994–2006Am J Trop Med Hyg200980458358719346380
   PubMed Web of Science ®Google Scholar
• YanJHuangBLiuGMeta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patientsActa Trop2013127323624423707647
   PubMed Web of Science ®Google Scholar
• TorreDCasariSSperanzaFRandomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study GroupAntimicrob Agents Chemother1998426134613499624473
   PubMed Web of Science ®Google Scholar
• TorresRAWeinbergWStansellJAtovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study GroupClin Infect Dis19972434224299114194
   PubMed Web of Science ®Google Scholar
• ChirgwinKHafnerRLeportCRandomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039Clin Infect Dis20023491243125011941551
   PubMed Web of Science ®Google Scholar
• JacobsonJMHafnerRRemingtonJDose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDSAIDS200115558358911316995
   PubMed Web of Science ®Google Scholar
• Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdfAccessed July 17, 2016
   Google Scholar
• HarrellMCarvounisPECurrent treatment of toxoplasma retinochoroiditis: an evidence-based reviewJ Ophthalmol2014201427350625197557
   PubMed Web of Science ®Google Scholar
• DoggettJSNilsenAForquerIEndochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosisProc Natl Acad Sci U S A201210939159361594123019377
   PubMed Web of Science ®Google Scholar
• BenmerzougaICheckleyLAFerdigMTArrizabalagaGWekRCSullivanWJJrGuanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosisAntimicrob Agents Chemother201559116939694526303803
   PubMed Web of Science ®Google Scholar
• AraujoFGHuskinson-MarkJGutteridgeWERemingtonJSIn vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondiiAntimicrob Agents Chemother19923623263301605598
   PubMed Web of Science ®Google Scholar
• McPhillieMZhouYEl BissatiKNew paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infectionsNature Publishing Group2016629179
   Google Scholar
• WattsEZhaoYDharaAEllerBPatwardhanASinaiAPNovel approaches reveal that Toxoplasma gondii bradyzoites within tissue cysts are dynamic and replicating entities in vivoMBio201565e01155e0111526350965
   PubMed Web of Science ®Google Scholar
• GajurelKGomezCADhakalRVogelHMontoyaJGFailure of primary atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipientsTranspl Infect Dis201618344645227016655
   PubMed Web of Science ®Google Scholar
• MeneceurPBouldouyreMAAubertDIn vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquoneAntimicrob Agents Chemother20085241269127718212105
   PubMed Web of Science ®Google Scholar
• AspinallTVJoynsonDHGuyEHydeJESimsPFThe molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosisJ Infect Dis2002185111637164312023770
   PubMed Web of Science ®Google Scholar
• DoliwaCXiaDEscotte-BinetSIdentification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE)Int J Parasitol Drugs Drug Resist20133354424533291
   PubMed Web of Science ®Google Scholar
• DoliwaCEscotte-BinetSAubertDSulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transportersParasite2013201923707894
   PubMed Web of Science ®Google Scholar
• McFaddenDCTomavoSBerryEABoothroydJCCharacterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistanceMol Biochem Parasitol2000108111210802314
   PubMed Web of Science ®Google Scholar
• AraujoFGHuskinsonJRemingtonJSRemarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondiiAntimicrob Agents Chemother19913522932992024964
   PubMed Web of Science ®Google Scholar
• ReynoldsMGOhJRoosDSIn vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductaseAntimicrob Agents Chemother20014541271127711257045
   PubMed Web of Science ®Google Scholar
• KimKA bradyzoite is a bradyzoite is a bradyzoite?Trends Parasitol2015311261061226515047
   PubMed Web of Science ®Google Scholar
• VidadalaRSRivasKLOjoKKDevelopment of an orally available and central nervous system (CNS)-penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitor with minimal human ether-a-go-go-related gene (hERG) activity for the treatment of toxoplasmosisJ Med Chem201659136531654627309760
   PubMed Web of Science ®Google Scholar
• LüderCGKReichardUGrossUChapter 7 – Toxoplasma Animal Models and TherapeuticsToxoplasma Gondii (Second Edition)BostonAcademic Press2014217255
   Google Scholar
• Paredes-SantosTCTomitaTYan FenMDevelopment of dual fluorescent stage specific reporter strain of Toxoplasma gondii to follow tachyzoite and bradyzoite development in vitro and in vivoMicrobes Infect2016181394726432517
   PubMed Web of Science ®Google Scholar
• SidikSMHuetDGanesanSMA genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genesCell2016166614231435.e1227594426
   PubMed Web of Science ®Google Scholar
• GajriaBBahlABrestelliJToxoDB: an integrated Toxoplasma gondii database resourceNucleic Acids Res200836Database issueD553D55618003657
   PubMed Web of Science ®Google Scholar
• NagamuneKBeattyWLSibleyLDArtemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondiiEukaryotic Cell200762147215617766463
   PubMed Web of Science ®Google Scholar
• NagamuneKMorenoSNJSibleyLDArtemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasisAntimicrob Agents Chemother2007513816382317698618
   PubMed Web of Science ®Google Scholar
• HolfelsEMcAuleyJMackDMilhousWKMcLeodRIn vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondiiAntimicrob Agents Chemother199438139213968092843
   PubMed Web of Science ®Google Scholar
• D’AngeloJGBordónCPosnerGHYolkenRJones-BrandoLArtemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycleJ Antimicrob Chemother20096314615018988681
   PubMed Web of Science ®Google Scholar
• SchultzTLHenckenCPWoodardLEA thiazole derivative of artemisinin moderately reduces Toxoplasma gondii cyst burden in infected miceJ Parasitol201410051652124524228
   PubMed Web of Science ®Google Scholar
• HenckenCPJones-BrandoLBordónCThiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondiiJ Med Chem2010533594360120373807
   PubMed Web of Science ®Google Scholar
• DrakeMTClarkeBLKhoslaSBisphosphonates: mechanism of action and role in clinical practiceMayo Clin Proc20088391032104518775204
   PubMed Web of Science ®Google Scholar
• LingYLiZ-HMirandaKOldfieldEMorenoSNJThe farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonatesJ Biol Chem2007282308043081617724033
   PubMed Web of Science ®Google Scholar
• MartinMBGrimleyJSLewisJCBisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapyJ Med Chem20014490991611300872
   PubMed Web of Science ®Google Scholar
• YardleyVKhanAAMartinMBIn vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondiiAntimicrob Agents Chemother20024692993111850291
   PubMed Web of Science ®Google Scholar
• JohnsonSMMurphyRCGeigerJADevelopment of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activityJ Med Chem20125552416242622320388
   PubMed Web of Science ®Google Scholar
• WinzerPMullerJAguado-MartinezAIn vitro and in vivo effects of the bumped kinase inhibitor 1294 in the related cyst-forming apicomplexans Toxoplasma gondii and Neospora caninumAntimicrob Agents Chemother201559106361637426248379
   PubMed Web of Science ®Google Scholar
• LouridoSShumanJZhangCShokatKMHuiRSibleyLDCalcium-dependent protein kinase 1 is an essential regulator of exocytosis in ToxoplasmaNature2010465729635936220485436
   PubMed Web of Science ®Google Scholar
• OjoKKLarsonETKeylounKRToxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitorsNat Struct Mol Biol201017560260720436472
   PubMed Web of Science ®Google Scholar
• MurphyRCOjoKKLarsonETDiscovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondiiACS Med Chem Lett20101733133521116453
   PubMed Web of Science ®Google Scholar
• SugiTKobayashiKTakemaeHIdentification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1Int J Parasitol Drugs Drug Resist201339310124533298
   PubMed Web of Science ®Google Scholar
• SugiTKawazuSHorimotoTKatoKA single mutation in the gatekeeper residue in TgMAPKL-1 restores the inhibitory effect of a bumped kinase inhibitor on the cell cycleInt J Parasitol Drugs Drug Resist2015511825941623
   PubMed Web of Science ®Google Scholar
• LarsonETOjoKKMurphyRCMultiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1J Med Chem20125562803281022369268
   PubMed Web of Science ®Google Scholar
• DoggettJSOjoKKFanEMalyDJVan VoorhisWCBumped kinase inhibitor 1294 treats established Toxoplasma gondii infectionAntimicrob Agents Chemother20145863547354924687502
   PubMed Web of Science ®Google Scholar
• LouridoSZhangCLopezMSOptimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondiiJ Med Chem20135673068307723470217
   PubMed Web of Science ®Google Scholar
• SugiTKatoKKobayashiK1NM-PP1 treatment of mice infected with Toxoplasma gondiiJ Vet Med Sci201173101377137921685719
   PubMed Web of Science ®Google Scholar
• HuangWOjoKKZhangZSAR studies of 5-aminopyrazole- 4-carboxamide analogues as potent and selective inhibitors of CDPK1ACS Med Chem Lett20156121184118926693272
   PubMed Web of Science ®Google Scholar
• ZhangZOjoKKJohnsonSMBenzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1Bioorg Med Chem Lett201222165264526722795629
   PubMed Web of Science ®Google Scholar
• ZhangZOjoKKVidadalaRPotent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffoldACS Med Chem Lett2013514044
   Web of Science ®Google Scholar
• MoineEDenevault-SabourinCDebierre-GrockiegoFA small-molecule cell-based screen led to the identification of biphenylimidazoazines with highly potent and broad-spectrum anti-apicomplexan activityEur J Med Chem20158938640025462254
   PubMed Web of Science ®Google Scholar
• MoineEDimier-PoissonIEnguehard-GueiffierCDevelopment of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1Eur J Med Chem20151058010526479029
   PubMed Web of Science ®Google Scholar
• PelphreyPMPopovVMJoskaTMHighly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysisJ Med Chem20075094095017269758
   PubMed Web of Science ®Google Scholar
• CanfieldCJMilhousWKAgerALPS-15: a potent, orally active antimalarial from a new class of folic acid antagonistsAm J Trop Med Hyg1993491211268352384
   PubMed Web of Science ®Google Scholar
• FidockDAWellemsTETransformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanilProc Natl Acad Sci U S A19979410931109369380737
   PubMed Web of Science ®Google Scholar
• MuiEJSchiehserGAMilhousWKNovel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivoPLoS Negl Trop Dis200823e19018320016
   PubMed Web of Science ®Google Scholar
• SmithMHPloeghHLWeissmanJSRoad to ruin: targeting proteins for degradation in the endoplasmic reticulumScience20113341086109022116878
   PubMed Web of Science ®Google Scholar
• HarbutMBPatelBAYeungBKSTargeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic designProc Natl Acad Sci U S A2012109214862149123236186
   PubMed Web of Science ®Google Scholar
• JelenskaJCrawfordMJHarbOSSubcellular localization of acetyl-CoA carboxylase in the apicomplexan parasite Toxoplasma gondiiProc Natl Acad Sci U S A2001982723272811226307
   PubMed Web of Science ®Google Scholar
• RobertsFRobertsCWJohnsonJJEvidence for the shikimate pathway in apicomplexan parasitesNature19983938018059655396
   PubMed Web of Science ®Google Scholar
• WallerRFKeelingPJDonaldRGNuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparumProc Natl Acad Sci U S A19989512352123579770490
   PubMed Web of Science ®Google Scholar
• MagnusonKJackowskiSRockCOCronanJERegulation of fatty acid biosynthesis in Escherichia coliMicrobiol Rev1993575225428246839
   PubMedGoogle Scholar
• McFaddenGIRoosDSApicomplexan plastids as drug targetsTrends Microbiol1999732833310431206
   PubMed Web of Science ®Google Scholar
• WakilSJStoopsJKJoshiVCFatty acid synthesis and its regulationAnnu Rev Biochem1983525375796137188
   PubMed Web of Science ®Google Scholar
• Martins-DuarteESCariasMVommaroRSuroliaNde SouzaWApicoplast fatty acid synthesis is essential for pellicle formation at the end of cytokinesis in Toxoplasma gondiiJ Cell Sci2016129173320333127457282
   PubMed Web of Science ®Google Scholar
• McLeodRMuenchSPRaffertyJBTriclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab IInt J Parasitol20013110911311239932
   PubMed Web of Science ®Google Scholar
• StecJFomovskaAAfanadorGAModification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondiiChemMedChem201381138116023776166
   PubMed Web of Science ®Google Scholar
• ChengGMuenchSPZhouYDesign, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductaseBioorg Med Chem Lett2013232035204323453069
   PubMed Web of Science ®Google Scholar
• MuenchSPStecJZhouYDevelopment of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptidesBioorg Med Chem Lett2013233551355523664871
   PubMed Web of Science ®Google Scholar
• SamuelBUHearnBMackDDelivery of antimicrobials into parasitesProc Natl Acad Sci U S A2003100142811428614623959
   PubMed Web of Science ®Google Scholar
• El-ZawawyLAEl-SaidDMossallamSFRamadanHSYounisSSTriclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosisExp Parasitol2015149546425499511
   PubMed Web of Science ®Google Scholar
• HevenerKEMehboobSSuP-CDiscovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matchingJ Med Chem20125526827922098466
   PubMed Web of Science ®Google Scholar
• WilkinsonCMcPhillieMJZhouYThe benzimidazole based drugs show good activity against T. gondii but poor activity against its proposed enoyl reductase enzyme targetBioorg Med Chem Lett20142491191624398298
   PubMed Web of Science ®Google Scholar
• JackowskiSMurphyCMCronanJERockCOAcetoacetyl-acyl carrier protein synthase. A target for the antibiotic thiolactomycinJ Biol Chem1989264762476292651445
   PubMed Web of Science ®Google Scholar
• Martins-DuarteÉSJonesSMGilbertIHAtellaGCde SouzaWVommaroRCThiolactomycin analogues as potential anti-Toxoplasma gondii agentsParasitol Int20095841141519698800
   PubMed Web of Science ®Google Scholar
• DrlicaKZhaoXDNA gyrase, topoisomerase IV, and the 4-quinolonesMicrobiol Mol Biol Rev1997613773929293187
   PubMed Web of Science ®Google Scholar
• PanXSFisherLMTargeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolonesAntimicrob Agents Chemother1997414714749021211
   PubMed Web of Science ®Google Scholar
• MartinezMMcDermottPWalkerRPharmacology of the fluoroquinolones: a perspective for the use in domestic animalsVet J2006172102816154368
   PubMed Web of Science ®Google Scholar
• KhanAASliferTAraujoFGRemingtonJSTrovafloxacin is active against Toxoplasma gondiiAntimicrob Agents Chemother199640185518598843293
   PubMed Web of Science ®Google Scholar
• GottsteinBRazmiGRAmmannPSagerHMüllerNToltrazuril treatment to control diaplacental Neospora caninum transmission in experimentally infected pregnant miceParasitology19991304148
   Web of Science ®Google Scholar
• BarbosaBFGomesAOFerroEAVNapolitanoDRMineoJRSilvaNMEnrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental modelsVet Parasitol2012187445222281151
   PubMed Web of Science ®Google Scholar
• KhanAAAraujoFGBrightyKEGootzTDRemingtonJSAnti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacinAntimicrob Agents Chemother1999431783178710390245
   PubMed Web of Science ®Google Scholar
• AnquetinGRouquayrolMMahmoudiNSynthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium sppBioorg Med Chem Lett2004142773277615125930
   PubMed Web of Science ®Google Scholar
• AnquetinGGreinerJMahmoudiNDesign, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolonesEur J Med Chem2006411478149317000032
   PubMed Web of Science ®Google Scholar
• DubarFWintjensRMartins-DuarteÉSEster prodrugs of ciprofloxacin as DNA-gyrase inhibitors: synthesis, antiparasitic evaluation and docking studiesMed Chem Commun20112430436
   Web of Science ®Google Scholar
• Martins-DuarteÉSDubarFLawtonPCiprofloxacin Derivatives Affect Parasite Cell Division and Increase the Survival of Mice Infected with Toxoplasma gondiiPLoS ONE201510e0125705012572325950173
   PubMed Web of Science ®Google Scholar
• AndrewsKTHaqueAJonesMKHDAC inhibitors in parasitic diseasesImmunol Cell Biol201190667722124373
   PubMed Web of Science ®Google Scholar
• VanagasLJeffersVBogadoSSDalmassoMCSullivanWJJrAngelSOToxoplasma histone acetylation remodelers as novel drug targetsExpert Rev Anti Infect Ther20141011891201
   Web of Science ®Google Scholar
• BougdourAMaubonDBaldacciPDrug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasitesJ Exp Med200920695396619349466
   PubMed Web of Science ®Google Scholar
• MaubonDBougdourAWongYSActivity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compoundsAntimicrob Agents Chemother2010544843485020713670
   PubMed Web of Science ®Google Scholar
• JeffersVGaoHCheckleyLALiuYFerdigMTSullivanWJJrGarcinol inhibits GCN5-mediated lysine acetyltransferase activity and prevents replication of the parasite Toxoplasma gondiiAntimicrob Agents Chemother2016602164217026810649
   PubMed Web of Science ®Google Scholar
• WangJDixonSETingL-MLysine acetyltransferase GCN5b interacts with AP2 factors and is required for Toxoplasma gondii proliferationPLoS Pathog201410e100383024391497
   PubMed Web of Science ®Google Scholar
• FomovskaAHuangQEl BissatiKNovel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathwayAntimicrob Agents Chemother2012562666268222354304
   PubMed Web of Science ®Google Scholar
• NgôHMYangMPaprotkaKPypaertMHoppeHJoinerKAAP-1 in Toxoplasma gondii mediates biogenesis of the rhoptry secretory organelle from a post-Golgi compartmentJ Biol Chem20032785343535212446678
   PubMed Web of Science ®Google Scholar
• BreinichMSFergusonDJPFothBJA dynamin is required for the biogenesis of secretory organelles in Toxoplasma gondiiCurr Biol20091927728619217293
   PubMed Web of Science ®Google Scholar
• KöhlerSDelwicheCFDennyPWA plastid of probable green algal origin in Apicomplexan parasitesScience1997275148514899045615
   PubMed Web of Science ®Google Scholar
• SeeberFBiosynthetic pathways of plastid-derived organelles as potential drug targets against parasitic apicomplexaCurr Drug Targets Immune Endocr Metabol Disord2003329910912769782
   PubMedGoogle Scholar
• AraujoFGGuptillDRRemingtonJSAzithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondiiAntimicrob Agents Chemother1988327557572840017
   PubMed Web of Science ®Google Scholar
• PfefferkornERNothnagelRFBorotzSEParasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutantAntimicrob Agents Chemother199236109110961510399
   PubMed Web of Science ®Google Scholar
• FicheraMERoosDSA plastid organelle as a drug target in apicomplexan parasitesNature19973904074099389481
   PubMed Web of Science ®Google Scholar
• LeeYChoiJYFuHChemistry and biology of macrolide antiparasitic agentsJ Med Chem2011542792280421428405
   PubMed Web of Science ®Google Scholar
• WebbMESmithAGAbellCBiosynthesis of pantothenateNat Prod Rep20042169572115565250
   PubMed Web of Science ®Google Scholar
• MageedSNCunninghamFHungAWPantothenic acid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapyAntimicrob Agents Chemother2014586345635325049241
   PubMed Web of Science ®Google Scholar
• HungAWSilvestreHLWenSCiulliABlundellTLAbellCApplication of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetaseAngew Chem Int20094884528456
   PubMed Web of Science ®Google Scholar
• SummertonJWellerDMorpholino antisense oligomers: design, preparation, and propertiesAntisense Nucleic Acid Drug Dev1997731871959212909
   PubMedGoogle Scholar
• LaiB-SWitolaWHEl BissatiKMolecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infectionsProc Natl Acad Sci U S A2012109141821418722891343
   PubMed Web of Science ®Google Scholar
• ZhouYFomovskaAMuenchSLaiBSMuiEMcLeodRSpiroindolone That Inhibits PfATPase4 Is a Potent, Cidal Inhibitor of Toxoplasma gondii Tachyzoites In Vitro and In Vivo. AntimicrobAgents Chemother20145817891792
   Web of Science ®Google Scholar
• VannierEKrausePJHuman babesiosisN Engl J Med2012366252397240722716978
   PubMed Web of Science ®Google Scholar
• CapperMJO’NeillPMFisherNAntimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1Proc Natl Acad Sci U S A2015112375576025564664
   PubMed Web of Science ®Google Scholar
• NilsenAMileyGPForquerIPDiscovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethersJ Med Chem20145793818383424720377
   PubMed Web of Science ®Google Scholar
• AldayPHBruzualINilsenAGenetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-quinolone-3-diarylethers and Antimycin in Toxoplasma gondiiAntimicrob Agents Chemother2016
   Web of Science ®Google Scholar
• SalzerWTAndersagHA new type of compound active against avian malariaChem Ber1948811219
   Google Scholar
• GingrichWDarrowEThe effect of endochin on experimental toxoplasmosisAm J Trop Med Hyg195131121714799708
   PubMed Web of Science ®Google Scholar
• MileyGPPouSWinterRELQ-300 prodrugs for enhanced delivery and single-dose cure of malariaAntimicrob Agents Chemother20155995555556026124159
   PubMed Web of Science ®Google Scholar
• LawresLAGargAKumarVRadical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquoneJ Exp Med2016 Epub66
   Web of Science ®Google Scholar
• VallieresCFisherNAntoineTHDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complexAntimicrob Agents Chemother20125673739374722547613
   PubMed Web of Science ®Google Scholar
• EschemannAGalkinAOettmeierWBrandtUKerscherSHDQ (1-hydroxy-2-dodecyl-4(1H)quinolone), a high affinity inhibitor for mitochondrial alternative NADH dehydrogenase: evidence for a ping-pong mechanismJ Biol Chem20052803138314215533932
   PubMed Web of Science ®Google Scholar
• HegewaldJGrossUBohneWIdentification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondiiMol Biochem Parasitol2013190161523747278
   PubMed Web of Science ®Google Scholar
• VercesiAERodriguesCOUyemuraSAZhongLMorenoSNRespiration and oxidative phosphorylation in the apicomplexan parasite Toxoplasma gondiiJ Biol Chem199827331040310479813002
   PubMed Web of Science ®Google Scholar
• MeloAMPBandeirasTMTeixeiraMNew insights into type II NAD(P)H:quinone oxidoreductasesMicrobiol Mol Biol Rev20046860361615590775
   PubMed Web of Science ®Google Scholar
• HegewaldJGroßUBohneWIdentification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondiiMol Biochem Parasitol201319061523747278
   PubMed Web of Science ®Google Scholar
• SalehAFriesenJBaumeisterSGroßUBohneWGrowth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenasesAntimicrob Agents Chemother2007511217122217242151
   PubMed Web of Science ®Google Scholar
• BajohrLLMaLPlatteCIn vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondiiAntimicrob Agents Chemother20105451752119884369
   PubMed Web of Science ®Google Scholar
• PidathalaCAmewuRPacorelBIdentification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH: quinone oxidoreductase (PfNDH2)J Med Chem2012551831184322364416
   PubMed Web of Science ®Google Scholar
• BeckfordFAThessingJShaloskiMSynthesis and characterization of mixed-ligand diimine-piperonal thiosemicarbazone complexes of ruthenium(II): biophysical investigations and biological evaluation as anticancer and antibacterial agentsJ Mol Struct2011992394721552381
   PubMed Web of Science ®Google Scholar
• BarnaFDebacheKVockCAKusterTHemphillAIn vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoitesAntimicrob Agents Chemother2013575747575423979747
   PubMed Web of Science ®Google Scholar
• FomovskaAWoodRDMuiESalicylanilide inhibitors of Toxoplasma gondiiJ Med Chem2012558375839122970937
   PubMed Web of Science ®Google Scholar
• RottmannMMcNamaraCYeungBKSSpiroindolones, a potent compound class for the treatment of malariaScience20103291175118020813948
   PubMed Web of Science ®Google Scholar
• GwiltPRTracewellWGPharmacokinetics and pharmacodynamics of hydroxyureaClin Pharmacokinet1998343473589592619
   PubMed Web of Science ®Google Scholar
• de MeloEJMayerhofferROde SouzaWHydroxyurea inhibits intracellular Toxoplasma gondii multiplicationFEMS Microbiol Lett2000185798210731610
   PubMed Web of Science ®Google Scholar
• LiuMCLinTSSartorelliACSynthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazoneJ Med Chem199235367236771433178
   PubMed Web of Science ®Google Scholar
• WalcourtALoyevskyMLovejoyDBGordeukVRRichardsonDRNovel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasitesInt J Biochem Cell Biol20043640140714687919
   PubMed Web of Science ®Google Scholar
• TenórioRPCarvalhoCSPessanhaCSSynthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activityBioorg Med Chem Lett2005152575257815863319
   PubMed Web of Science ®Google Scholar
• de AquinoTMLiesenAPda SilvaREASynthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acidsBioorg Med Chem20081644645617905587
   PubMed Web of Science ®Google Scholar
• LiesenAPde AquinoTMCarvalhoCSSynthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazolesEur J Med Chem2010453685369120541294
   PubMed Web of Science ®Google Scholar
• DzitkoKPanethAPlechT1,4-Disubstituted thiosemicarbazide derivatives are potent inhibitors of Toxoplasma gondii proliferationMolecules2014199926994325010466
   PubMed Web of Science ®Google Scholar
• WoodwardKNToxicological Effects of Veterinary Medical Products in Humans2Cambridge, UKThe Royal Society of Chemistry2013
   Google Scholar
• MitchellSMZajacAMDavisWLLindsayDSEfficacy of ponazuril in vitro and in preventing and treating Toxoplasma gondii infections in miceJ Parasitol20049063964215270113
   PubMed Web of Science ®Google Scholar
• Martins-DuarteÉDSde SouzaWVommaroRCItraconazole affects Toxoplasma gondii endodyogenyFEMS Microbiol Lett200828229029818371067
   PubMed Web of Science ®Google Scholar
• Martins-DuarteÉSLemgruberLde SouzaWVommaroRCToxoplasma gondii: fluconazole and itraconazole activity against toxoplasmosis in a murine modelExp Parasitol201012446646920045696
   PubMed Web of Science ®Google Scholar
• DzitkoKPanethAPlechTPaweczykJWgliskaLPanethPTriazole-based compound as a candidate to develop novel medicines to treat toxoplasmosisAntimicrob Agents Chemother2014587583758525288090
   PubMed Web of Science ®Google Scholar
• KrivogorskyBGrundtPYolkenRJones-BrandoLInhibition of Toxoplasma gondii by indirubin and tryptanthrin analogsAntimicrob Agents Chemother2008524466446918824607
   PubMed Web of Science ®Google Scholar
• KrivogorskyBNelsonACDouglasKAGrundtPTryptanthrin derivatives as Toxoplasma gondii inhibitors – structure-activity-relationship of the 6-positionBioorg Med Chem Lett2013231032103523321561
   PubMed Web of Science ®Google Scholar